trial

Intramuscular (IM) Olanzapine Versus IM Haloperidol Plus Lorazepam for Acute Agitation in Schizophrenia

NCTId NCT00797277
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 67 (actual)
Sponsored by National Taiwan University Hospital
Primary completion 2009-06
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
67 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
None
Start
2006-07
Primary completion
2009-06
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
OlanzapineHaloperidol

Sponsors

National Taiwan University HospitalLead Sponsor
Yu-Li HospitalCollaborator

Investigators

1
Tzung-Jeng Hwang, MD, MPH, PhDStudy Director

Sites

1 total
Taipei, Taiwan

Linked catalysts

1
Intramuscular (IM) Olanzapine Versus IM Haloperidol Plus Lorazepam for Acute Agi — primary completion2009-06

Facts & assertions

4 sourced
Enrollment
67
Phase
PHASE3
Primary Completion Date
2009-06
Status
COMPLETED
relationships
The graph out of here
drug
Olanzapine
drug
Haloperidol
drug
lead_sponsor
National Taiwan University Hospital
company
collaborator
Yu-Li Hospital
company
indication
Psychomotor Agitation
indication
Schizoaffective Disorder
indication
Psychotic Disorders
indication
investigator
Tzung-Jeng Hwang, MD, MPH, PhD
person